Trial Profile
VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer to Examine Safety, Tolerability, and Immune Response to the Investigational VEGFR-2 DNA Vaccine VXM01
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Jul 2022
Price :
$35
*
At a glance
- Drugs VXM-01 (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions; First in man
- Sponsors VAXIMM
- 07 Jun 2016 Results from extension part of this trial (n=26) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 19 May 2016 According to an VAXIMM media release, data from this trial will be presented at the upcoming Annual Meeting of the American Society of Clinical Oncology (ASCO).
- 05 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.